Literature DB >> 22961398

The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells.

Hanh T Q Nguyen1, Vincent Murray.   

Abstract

Bleomycin is an antibiotic drug that is widely used in cancer chemotherapy. Telomeres are located at the ends of chromosomes and comprise the tandemly repeated DNA sequence (GGGTTA)( n ) in humans. Since bleomycin cleaves DNA at 5'-GT dinucleotide sequences, telomeres are expected to be a major target for bleomycin cleavage. In this work, we determined the DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells. This was accomplished using a linear amplification procedure, a fluorescently labelled oligonucleotide primer and capillary gel electrophoresis with laser-induced fluorescence detection. This represents the first occasion that the DNA sequence specificity of bleomycin cleavage in telomeric DNA sequences in human cells has been reported. The bleomycin DNA sequence selectivity was mainly at 5'-GT dinucleotides, with lesser amounts at 5'-GG dinucleotides. The cellular bleomycin telomeric DNA damage was also compared with bleomycin telomeric damage in purified human genomic DNA and was found to be very similar. The implications of these results for the understanding of bleomycin's mechanism of action in human cells are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961398     DOI: 10.1007/s00775-012-0934-8

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  54 in total

1.  TIN2, a new regulator of telomere length in human cells.

Authors:  S H Kim; P Kaminker; J Campisi
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

Review 2.  A survey of the sequence-specific interaction of damaging agents with DNA: emphasis on antitumor agents.

Authors:  V Murray
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1999

3.  Cleavage of Nucleic Acids by Bleomycin.

Authors:  Richard M. Burger
Journal:  Chem Rev       Date:  1998-05-07       Impact factor: 60.622

4.  PTOP interacts with POT1 and regulates its localization to telomeres.

Authors:  Dan Liu; Amin Safari; Matthew S O'Connor; Doug W Chan; Andrew Laegeler; Jun Qin; Zhou Songyang
Journal:  Nat Cell Biol       Date:  2004-06-06       Impact factor: 28.824

5.  A comparative analysis of bleomycin-induced incomplete chromosome elements in two mammalian cell lines using a telomeric PNA probe.

Authors:  María C Díaz Flaqué; Martha S Bianchi; Alejandro D Bolzán
Journal:  Environ Mol Mutagen       Date:  2006-12       Impact factor: 3.216

6.  The sequence specificity of bleomycin damage in three cloned DNA sequences that differ by a small number of base substitutions.

Authors:  V Murray; L Tan; J Matthews; R F Martin
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

7.  A clinical review of bleomycin--a new antineoplastic agent.

Authors:  R H Blum; S K Carter; K Agre
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

8.  Studies of metallobleomycins by electronic spectroscopy, electron spin resonance spectroscopy, and potentiometric titration.

Authors:  Y Sugiura; K Ishizu; K Miyoshi
Journal:  J Antibiot (Tokyo)       Date:  1979-05       Impact factor: 2.649

9.  The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence.

Authors:  Moumita Paul; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2011-04-05       Impact factor: 3.358

Review 10.  Telomere-driven genomic instability in cancer cells.

Authors:  Chantal Desmaze; Jean-Charles Soria; Marie-Anne Freulet-Marrière; Noelle Mathieu; Laure Sabatier
Journal:  Cancer Lett       Date:  2003-05-15       Impact factor: 8.679

View more
  7 in total

1.  The DNA sequence specificity of bleomycin cleavage in a systematically altered DNA sequence.

Authors:  Shweta D Gautam; Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2017-05-16       Impact factor: 3.358

2.  Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.

Authors:  Jon K Chen; Dong Yang; Ben Shen; Brett A Neilan; Vincent Murray
Journal:  Bioorg Med Chem       Date:  2016-09-30       Impact factor: 3.641

3.  The genome-wide DNA sequence specificity of the anti-tumour drug bleomycin in human cells.

Authors:  Vincent Murray; Jon K Chen; Mark M Tanaka
Journal:  Mol Biol Rep       Date:  2016-05-17       Impact factor: 2.316

4.  The anti-tumor drug bleomycin preferentially cleaves at the transcription start sites of actively transcribed genes in human cells.

Authors:  Vincent Murray; Jon K Chen; Anne M Galea
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

5.  The determination of the DNA sequence specificity of bleomycin-induced abasic sites.

Authors:  Jon K Chen; Vincent Murray
Journal:  J Biol Inorg Chem       Date:  2016-03-03       Impact factor: 3.358

6.  MutS homologue hMSH5: recombinational DSB repair and non-synonymous polymorphic variants.

Authors:  Xiling Wu; Yang Xu; Katey Feng; Joshua D Tompkins; Chengtao Her
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

Review 7.  The Interaction of the Metallo-Glycopeptide Anti-Tumour Drug Bleomycin with DNA.

Authors:  Vincent Murray; Jon K Chen; Long H Chung
Journal:  Int J Mol Sci       Date:  2018-05-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.